Keyword: Takeda

Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.

Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.

Takeda sold its Brazil-based unit Multilab right after it confirmed its plan to buy Shire, and now it's reportedly mulling another sale in the region.

CDMOs Cambrex and Ajinomoto Bio-Pharma Services upgraded manufacturing plants, Takeda scored an albumin approval via its Shire deal, and more.

J&J's Darzalex is on track to nab a second first-line myeloma nod in the U.S., but its reimbursement journey in England hasn't been so smooth.

Daiichi rejigs management; China approves its first biosimilar; Sinovac uses a poison pill to fend off an investor takeover.

Takeda's gout drug Uloric just got pushed out of the first-line treatment club, thanks to data showing it increases the risk of death.

Takeda’s partnership with Microsoft and Eurodis to take on rare disease delivered initial results this week with a road map to shorten the time to diagnosis.

Novo faces a tough task as several long-acting factor VIII therapies are already on the market, and Roche's antibody drug Hemlibra is zooming ahead.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.